Bonviva (Ibandronic Acid Sodium Monohydrate)
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.
MFDS item code 200611518 · Approved 2006.11.23 · Insurance code 645406251
Treatment of osteoporosis in postmenopausal women
This medication is used for the treatment of osteoporosis in postmenopausal women. It helps to improve bone weakening caused by the decrease in female hormones after menopause, thereby reducing the risk of fractures.
Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as supplements. If a dose is missed on the scheduled dosing day, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. There is insufficient clinical experience in patients with serum creatinine exceeding 200 µmol/L(2.3mg/dL) or creatinine clearance less than 30ml/min, and administration of this medicine is not recommended for these patients. Elderly No dose adjustment is necessary.
Efficacy and safety have not been studied in children 18 years of age and younger.
This medication must be administered intravenously. Caution is required as injection into arteries or around veins can cause tissue damage. This medication should not be used in patients with allergy to the drug or its components, or in patients with untreated hypocalcemia. During treatment, side effects such as indigestion, abdominal pain, nausea, headache, rash, myalgia, and arthralgia may occur, but most are mild to moderate and do not warrant discontinuation of therapy. Occasionally, influenza-like symptoms such as fever, chills, fatigue, myalgia, and arthralgia may appear, but these symptoms generally resolve naturally within a short period. Prolonged use of this drug may rarely cause osteonecrosis of the jaw or bones surrounding the ear; therefore, especially for cancer patients or those undergoing dental treatment, it is advisable to have an oral examination before administration. If dental treatment is necessary, excessive dental procedures should be avoided while taking this medication, and decisions about whether to discontinue treatment should be made in consultation with a specialist. This medication may temporarily lower serum calcium levels, so it is important to treat hypocalcemia or bone metabolic disorders before administration and ensure sufficient intake of calcium and vitamin D. Patients with impaired kidney function or who are taking medications affecting the kidneys require regular monitoring and observation. During administration of this medication, sudden allergic reactions or anaphylaxis may occur; therefore, it should be given in an environment where emergency treatment is available. Women who are pregnant or breastfeeding are advised not to use this medication due to the lack of established safety. Overdose may cause issues with the kidneys and liver; if an overdose is suspected, immediate consultation with medical personnel and appropriate treatment is required. This medication should not be mixed with other intravenous medications or calcium-containing solutions, and it must be administered using a separate intravenous line. After administration, monitor closely for any adverse reactions, and report any abnormal symptoms to medical personnel immediately.
Gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illnesses, fatigue, headache, rash, bone pain, weakness, injection site reactions, phlebitis, thrombophlebitis, hypersensitivity reactions, angioedema, facial swelling, edema, urticaria, uveitis, episcleritis, scleritis, anaphylactic reactions, shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical electronic fractures, intertrochanteric femoral fractures, osteonecrosis of the jaw and outer ear canal, dizziness, optic atrophy, lower motor neuron lesions, tremors, unspecified gastrointestinal disorders, benign gastrointestinal neoplasms, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, skin desquamation, acute renal failure, sensory loss
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent exposure to air and moisture, and the storage temperature should be maintained at room temperature between 1 degree and 30 degrees Celsius. This helps to maintain the efficacy of the medication and prevent degradation.
A colorless, transparent solution filled in a prefilled syringe with a single-use injection needle attached.
1 prefilled syringe
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.